Contrasting Beigene (ONC) & The Competition

Beigene (NASDAQ:ONC) is one of 1,070 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it weigh in compared to its competitors? We will compare Beigene to similar companies based on the strength of its profitability, valuation, institutional ownership, risk, dividends, analyst recommendations and earnings.

Insider & Institutional Ownership

48.5% of Beigene shares are owned by institutional investors. Comparatively, 44.1% of shares of all “Pharmaceutical preparations” companies are owned by institutional investors. 7.4% of Beigene shares are owned by company insiders. Comparatively, 13.7% of shares of all “Pharmaceutical preparations” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Beigene and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Beigene	-25.94%	-25.12%	-14.95%
Beigene Competitors	-3,399.87%	-235.11%	-32.77%

Earnings and Valuation

This table compares Beigene and its competitors gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Beigene	$3.81 billion	-$881.71 million	-43.55
Beigene Competitors	$9.93 billion	$136.87 million	-7.56

Beigene’s competitors have higher revenue and earnings than Beigene. Beigene is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Beigene and its competitors, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Beigene	0	0	3	0	3.00
Beigene Competitors	8362	22178	50293	1345	2.54

Beigene presently has a consensus target price of $310.00, suggesting a potential upside of 15.94%. As a group, “Pharmaceutical preparations” companies have a potential upside of 218.73%. Given Beigene’s competitors higher probable upside, analysts plainly believe Beigene has less favorable growth aspects than its competitors.

Risk & Volatility

Beigene has a beta of 0.65, indicating that its share price is 35% less volatile than the S&P 500. Comparatively, Beigene’s competitors have a beta of 3.64, indicating that their average share price is 264% more volatile than the S&P 500.

Summary

Beigene competitors beat Beigene on 7 of the 13 factors compared.

About Beigene

BeiGene Ltd. Is a global oncology company, which engages in providing pharmaceutical products. Its medicines include BRUKINSA, TEVIMBRA, and PARTRUVIX. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in George Town, KY.